Gan

Qiming Venture Partners Nisa Leung and Duane Kuang Made the 2023 Forbes Midas List

Retrieved on: 
Friday, May 5, 2023
Venus, Cloud, Roborock, Forbes China Celebrity 100, Female, Qiming Venture Partners, Midas List, Gan, CYG, Gold, Investment, CanSino Biologics, Mobile robot, T&C, VC, WeRide, Duane, Unisound, Pharmaceutical industry

SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.

Key Points: 
  • SHANGHAI, May 5, 2023 /PRNewswire/ -- The 2023 Forbes Midas List, a prestigious industry list of world's best venture capital investors, was unveiled.
  • Qiming Venture Partners Managing Partner Nisa Leung and Founding Managing Partner Duane Kuang made the list.
  • Nisa Leung has become a Forbes Midas Lister for the fifth year in a row, placing 41st this year.
  • Duane Kuang made the Forbes Midas List for the fourth time, ranking 70th this year.

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Retrieved on: 
Sunday, January 22, 2023
General counsel, Warner Chilcott, CMC, Regulatory News Service, Master of Pharmacy, CET, United States Department of the Navy, Pharmacovigilance, MD, Johnson & Johnson, Pfizer, Good laboratory practice, Good manufacturing practice, Capsule, Eastern University, Sri Lanka, NDA, BA, Good clinical laboratory practice, Patient, Organization, Regulatory affairs, SLT, Therapy, Charcot–Marie–Tooth disease, Cellectis, Eastern University, Master of Science, Quality assurance, Tablet, Scott, Bachelor of Science, Gan, Doctor of Philosophy, Neurodegeneration, Hugo, Management, Pharmaceutical industry, Medical device, Sanofi, Quality

Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality

Key Points: 
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Pharnext strengthens its Senior Leadership Team with the appointment of Scott Johnson as VP, Head of Quality
    PARIS, France, January 4th, 2023, 08:30 am CET – Pharnext SA (FR001400BV89 - ALPHA) (the “Company”), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical need, today announces the appointment of Scott Johnson as VP, Head of Quality.
  • Prior to Oyster, Scott served as Director, Quality Assurance at Lupin Pharmaceuticals where he had overall responsibility for quality and compliance.
  • Hugo Brugière, Chairman and Chief Executive Officer of Pharnext, commented: “I look forward to working with Scott and am delighted to welcome him to the Pharnext Senior Leadership Team.

Qiming Venture Partners portfolio Transwarp successfully lists on STAR Market

Retrieved on: 
Tuesday, October 18, 2022
Venus, CanSino Biologics, Qiming Venture Partners, Health care, Government, Transport, Growth, Technology, Partner, NYSE, NASDAQ, HKEX, IPO, Shanghai Stock Exchange, Shenzhen Stock Exchange, RMB, San Francisco Bay Area, Software, Initial public offering, STAR, Industry, Big data, Information technology, CEO, UBtech Robotics, Gan, T&C, Mining, Bank, Security (finance), Warp drive

SHANGHAI, Oct. 17, 2022 /PRNewswire/ -- Transwarp, a Qiming Venture Partners portfolio company and China's leading software developer of enterprise big data infrastructure, successfully lists on the STAR board of Shanghai Stock Exchange today.

Key Points: 
  • SHANGHAI, Oct. 17, 2022 /PRNewswire/ -- Transwarp, a Qiming Venture Partners portfolio company and China's leading software developer of enterprise big data infrastructure, successfully lists on the STAR board of Shanghai Stock Exchange today.
  • Transwarp's successful IPO is also the 7th IPO for Qiming Venture Partners since the beginning of 2022.
  • Kuantai Yeh, Partner of Qiming Venture Partners, said, "I am glad to witness another milestone moment of Transwarp.
  • Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.4 billion in capital raised.

Qiming's Nisa Leung, Duane Kuang Named on 2022 Forbes Midas List

Retrieved on: 
Wednesday, April 13, 2022
Venus, ZH, Forbes China Celebrity 100, Health, Hong Kong Exchanges and Clearing, Duane, CanSino Biologics, Poverty, Taipei Exchange, NASDAQ, Social responsibility, VC, Partner, Science, San Francisco Bay Area, AUM, Gan, Midas List, CNY, ESG, Gold, Artificial intelligence, PharmAccess Foundation, Efficiency, Shenzhen Stock Exchange, LP record, Technology, Environment, Ecosystem, Female, AI, NYSE, Semiconductor, Xiaomi, TMT, Blockchain, Software as a service, Forbes, Shanghai Stock Exchange, Food delivery, Healthcare, Pharmaceutical industry, Renewable energy, Bank, UBtech Robotics, Unisound, Midas, Qiming Venture Partners

SHANGHAI, April 12, 2022 /PRNewswire/ Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists.

Key Points: 
  • SHANGHAI, April 12, 2022 /PRNewswire/ Forbes released the 2022 Midas List on April 12, a ranking of the world's top 100 venture capitalists.
  • Nisa Leung, Managing Partner of Qiming Venture Partners, and Duane Kuang, Founding Managing Partner of Qiming Venture Partners, ranked on the list.
  • Nisa has been on the list for four consecutive years, ranking No.61 and up 12 places from last year.
  • Duane has been named on the Midas list for the third time, ranking No.74 this year.

Qiming's Portfolio Company Rendu Biotechnology Lists on STAR Market

Retrieved on: 
Wednesday, March 30, 2022
Venus, Qiming Venture Partners, CanSino Biologics, Biotechnology, USD, Respiration, NASDAQ, Shanghai Stock Exchange STAR Market, SESH, Shanghai Stock Exchange, Diagnosis, National Medical Products Administration, CDC, Shenzhen Stock Exchange, Growth, NYSE, Star Market, ZH, Centers for Disease Control and Prevention, Digestion, Hepatitis, Hospital, Hong Kong Exchanges and Clearing, Science, CNY, RNA, NMPA, UBtech Robotics, RMB, SAT, Center, Technology, AUM, Gan, Time, COVID-19, TMT, San Francisco Bay Area, Partner, Solution, HBV, IPO, Blood, Frost & Sullivan, Food, Taipei Exchange, Reproduction, Fine chemical, Security (finance), Vaccine, Rendu

SHANGHAI, March 29, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company Rendu Biotechnology (SESH: 688193), a leader in RNA molecular diagnostics in China, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.

Key Points: 
  • SHANGHAI, March 29, 2022 /PRNewswire/ -- Qiming Venture Partners' portfolio company Rendu Biotechnology (SESH: 688193), a leader in RNA molecular diagnostics in China, today listed on the Science and Technology Innovation Board (the "STAR Market") of the Shanghai Stock Exchange.
  • Qiming Venture Partners is the earliest investor in Rendu Biotechnology and led the company's Series A financing round in 2013.
  • The successful listing of Rendu also marks the third IPO in Qiming's portfolio in 2022.
  • In addition, Rendu Biotechnology launched AutoSAT, the first fully automatic, high-throughput, and full-process integrated platform for nucleic acid detection in China's molecular diagnostic space.

Qiming Venture Partners Welcomes David Chu as IR Partner

Retrieved on: 
Wednesday, March 2, 2022
Venus, Partners Group, Shenzhen Stock Exchange, Qiming Venture Partners, AUM, Taipei Exchange, USD, Partner, Hong Kong Exchanges and Clearing, NYSE, TMT, CanSino Biologics, NASDAQ, UBtech Robotics, Gan, History, Technology, San Francisco Bay Area, Partnership, Publication, Shanghai Stock Exchange, ZH, Pharmaceutical industry, Private investigator, Bank

SHANGHAI, March 1, 2022 /PRNewswire/ -- Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that David Chu has joined the firm as a Partner, focusing on fundraising and investor relations for Qiming's USD funds.

Key Points: 
  • SHANGHAI, March 1, 2022 /PRNewswire/ -- Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that David Chu has joined the firm as a Partner, focusing on fundraising and investor relations for Qiming's USD funds.
  • He has over 20 years of experience in the venture capital ecosystem as a limited partner, financial advisor to entrepreneurs, and venture capitalist.
  • David Chu said, "I am excited to be joining Qiming, a firm I have admired for its exceptional investment track record and outstanding reputation amongst entrepreneurs and limited partners.
  • Grace Lee, Partner & Group COO, said, "David has brought with him more than a decade of limited partner and venture capital experience.

Investigation Report on China's Insulin Glargine Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 7, 2022
Health, Diabetes, COVID-19, CAGR, Growth, Insulin glargine, Research, Patient, Insulin, Diabetes, Gan, Diagnosis, Sanofi, Medical device, Pharmaceutical industry

The "Investigation Report on China's Insulin Glargine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Insulin Glargine Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The CAGR of the sales value of Insulin Glargine in the Chinese market is 5.45% from 2016 to 2020.
  • In addition, the key patent of Insulin Glargine expired in 2015, and more generic drugs will appear in the Insulin Glargine market in the future.
  • 2 Sales of Insulin Glargine in China, 2016-2020
    2.3 Sales of Insulin Glargine by Dosage Form in China, 2016-2020
    3 Analysis of Major Insulin Glargine Manufacturers in China, 2016-2020
    3.3.2 Sales of BASALIN (Gan&Lee Pharmaceuticals Co., Ltd.'s Insulin Glargine) in China
    3.4 Zhuhai United Laboratories Co., Ltd.
    3.4.2 Sales of USLEN (Zhuhai United Laboratories Co., Ltd.'s Insulin Glargine) in China
    4 Prices of Insulin Glargine for Different Manufacturers in China, 2020-2021
    4.3 Zhuhai United Laboratories Co., Ltd. (USLEN)
    5 Prospect of Chinese Insulin Glargine Market, 2021-2025
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005250/en/

Qiming Venture Partners Announces Annual Promotions

Retrieved on: 
Friday, January 7, 2022
Venus, Hong Kong Exchanges and Clearing, UBtech Robotics, Internet, Shenzhen Stock Exchange, Patient, NYSE, TMT, CanSino Biologics, Taipei Exchange, Gan, Qiming Venture Partners, NASDAQ, Shanghai Stock Exchange, ZH, AUM, San Francisco Bay Area, Generation Z, Technology, Security (finance), Partner

SHANGHAI, Jan. 7, 2022 /PRNewswire/ -- Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce the promotions of Bonnie Wang and Dr. Kan Chen to Partner, and Xiaofei Zhou to Vice President.

Key Points: 
  • SHANGHAI, Jan. 7, 2022 /PRNewswire/ -- Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce the promotions of Bonnie Wang and Dr. Kan Chen to Partner, and Xiaofei Zhou to Vice President.
  • Dr. Kan Chen joined Qiming Venture Partners in 2016, where he was involved with several industry-leading companies in the innovative drug sector.
  • Qiming Venture Partners congratulates the eleven team members on their promotions and accomplishments.
  • Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Shiyu Wang Rejoins Qiming Venture Partners as Partner, Co-Leads TMT Team

Retrieved on: 
Tuesday, January 4, 2022
Venus, Growth, Partner, Culture, Taipei Exchange, Social, Hong Kong Exchanges and Clearing, TMT, UBtech Robotics, Qiming Venture Partners, CanSino Biologics, NASDAQ, Partnership, LP, San Francisco Bay Area, Gan, NYSE, Publication, Shenzhen Stock Exchange, ZH, AUM, Shanghai Stock Exchange, History, Time, Internet, Financial services

SHANGHAI, Jan. 3, 2022 /PRNewswire/ -- Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that Shiyu Wang has rejoined the firm as a Partner.

Key Points: 
  • SHANGHAI, Jan. 3, 2022 /PRNewswire/ -- Qiming Venture Partners, a leading venture capital firm in China, is pleased to announce that Shiyu Wang has rejoined the firm as a Partner.
  • Shiyu Wang has many years of investment experience in the internet and consumer industries, having previously worked at Qiming Venture Partners from 2012 to 2016.
  • From start-up to rapid growth, Qiming Venture Partners, as a venture capital firm in China, has gone through 15 years of history.
  • Qiming Venture Partners has also been ranked as a leading fund in China's venture capital industry by numerous agencies and publications.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for a Novel Glucagon-Like Peptide-1 Analogue, GZR18

Retrieved on: 
Monday, December 6, 2021
Patient, Degenerative disease, Internet, Insulin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Investigational New Drug, Cancer, MBA, IND, Blood, Doctor of Philosophy, Glucagon-like peptide-1 receptor, Therapy, Glucagon, Gan, Lists of diseases, FDA, Roy Taylor (scientist), Food, Type 2 diabetes, Pharmaceutical industry

BEIJING andBRIDGEWATER, N.J., Dec. 6, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company's compound, GZR18, to improve the management of type 2 diabetes mellitus.

Key Points: 
  • BEIJING andBRIDGEWATER, N.J., Dec. 6, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the company's compound, GZR18, to improve the management of type 2 diabetes mellitus.
  • This IND acceptance by the FDA will allow Gan & Lee to proceed with GZR18 Phase 1 clinical trial.
  • Gan & Lee Pharmaceuticalshasdeveloped the first Chinese domestic biosynthetic human insulin.
  • In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment.